Similarly, in colorectal cancer, SETDB1 overexpression facilitates cell proliferation by activating AKT, and inhibition of SETDB1 augments the sensitivity of cetuximab in colorectal cancer [127]. Here, AKT1 is linked to colorectal cancer.